BackgroundDepressive symptoms are common among individuals with chronic low back pain (CLBP) and are associated with poorer treatment outcomes. Although sleep problems are frequently reported in this population, the dose-response association between sleep duration and depressive symptoms remains unclear.ObjectiveThis study aimed to examine the association between sleep duration and elevated depressive symptoms among U.S. adults with CLBP and to evaluate whether this association showed a nonlinear or threshold pattern.MethodsThis cross-sectional study analyzed adults with CLBP from the 2009-2010 National Health and Nutrition Examination Survey (NHANES). Depressive symptoms were assessed using the Patient Health Questionnaire-9. Survey-weighted multivariable logistic regression and restricted cubic spline analyses were performed.ResultsAmong 568 adults with CLBP, 135 (23.8%) had elevated depressive symptoms. In the fully adjusted survey-weighted model, compared with participants reporting severely insufficient sleep (≤5 h), those sleeping 5-6 h and 7-8 h had significantly lower odds of elevated depressive symptoms, with ORs of 0.31 (95% CI: 0.13-0.76) and 0.51 (95% CI: 0.29-0.88), respectively. Restricted cubic spline analysis showed an L-shaped association, with an inflection point at approximately 6.8 h.ConclusionInsufficient sleep duration was significantly associated with higher depressive symptom burden in individuals with CLBP. Sleep duration may be a clinically relevant marker for identifying depressive symptom burden in this population.
Hui-Fang Su, Kai-Ying He, Xian-Dong Liu· Journal of Back and Musculos...· 0 citations
Background We investigated the association between food-derived dietary magnesium intake and all-cause mortality among adults with chronic kidney disease. Methods We analysed data from adults aged ≥20 years with CKD who participated in the National Health and Nutrition Examination Survey between 1999 and 2018. Mortality status was ascertained through linkage to the National Death Index through 31 December 2019. Multivariable Cox proportional hazards models were used to evaluate the association between dietary magnesium intake and all-cause mortality. Restricted cubic spline analysis, Kaplan–Meier survival analysis, subgroup analyses, and sensitivity analyses were also performed. Results A total of 8,104 CKD patients were included in this cohort study with a median follow-up of 85 months, during which 3,134 (38.7%) died from all causes. In the fully adjusted Cox model, each 100 mg/day increase in dietary magnesium intake was associated with a 7.5% lower risk of all-cause mortality (HR = 0.925, 95% CI 0.881–0.971; P = 0.002). Compared with the lowest quartile, adjusted hazard ratios were 0.978 (95% CI 0.883–1.083) for Q2, 0.904 (95% CI 0.804–1.016) for Q3, and 0.866 (95% CI 0.744–1.007) for Q4, with a significant trend across quartiles (P for trend = 0.036). RCS analysis demonstrated a significant overall association with no evidence of nonlinearity (P for overall association = 0.009; P for nonlinearity = 0.472). Kaplan–Meier analysis showed higher survival probabilities among participants with higher dietary magnesium intake. Conclusions Higher dietary magnesium intake was independently associated with a lower risk of all-cause mortality among adults with CKD. These findings suggest that adequate dietary magnesium intake may represent an important nutritional factor associated with prognosis in CKD. Further prospective studies and randomised clinical trials are warranted to determine whether increasing dietary magnesium intake can improve clinical outcomes. Summary statement Higher dietary magnesium intake was independently associated with lower all-cause mortality among patients with chronic kidney disease in NHANES 1999–2018. These findings highlight the potential protective role of adequate magnesium intake in improving long-term survival in this population.
Zi-Yan Xu, Jing Zou, Li-Jun Xie et al.· Clinical medicine (London)· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
